More specifically, lupus-prone mice treated with JAK2-STAT1 inhibitors, JAK1-STAT3 inhibitors, selective STAT3 inhibitors, and tofacitinib showed reduced serum levels of anti-dsDNA antibodies (20, 24, 27). Here, JAK1 is linked to systemic lupus erythematosus.